1. Home
  2. ANAB vs NRIM Comparison

ANAB vs NRIM Comparison

Compare ANAB & NRIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • NRIM
  • Stock Information
  • Founded
  • ANAB 2005
  • NRIM 1990
  • Country
  • ANAB United States
  • NRIM United States
  • Employees
  • ANAB N/A
  • NRIM N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • NRIM Savings Institutions
  • Sector
  • ANAB Health Care
  • NRIM Finance
  • Exchange
  • ANAB Nasdaq
  • NRIM Nasdaq
  • Market Cap
  • ANAB 630.2M
  • NRIM 514.9M
  • IPO Year
  • ANAB 2017
  • NRIM N/A
  • Fundamental
  • Price
  • ANAB $21.90
  • NRIM $90.90
  • Analyst Decision
  • ANAB Buy
  • NRIM
  • Analyst Count
  • ANAB 10
  • NRIM 0
  • Target Price
  • ANAB $48.00
  • NRIM N/A
  • AVG Volume (30 Days)
  • ANAB 465.1K
  • NRIM 47.3K
  • Earning Date
  • ANAB 11-04-2025
  • NRIM 10-22-2025
  • Dividend Yield
  • ANAB N/A
  • NRIM 2.82%
  • EPS Growth
  • ANAB N/A
  • NRIM 38.28
  • EPS
  • ANAB N/A
  • NRIM 7.99
  • Revenue
  • ANAB $123,164,000.00
  • NRIM $175,041,000.00
  • Revenue This Year
  • ANAB $11.22
  • NRIM N/A
  • Revenue Next Year
  • ANAB $8.35
  • NRIM $8.63
  • P/E Ratio
  • ANAB N/A
  • NRIM $11.38
  • Revenue Growth
  • ANAB 304.17
  • NRIM 28.34
  • 52 Week Low
  • ANAB $12.21
  • NRIM $63.68
  • 52 Week High
  • ANAB $40.70
  • NRIM $100.21
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 52.43
  • NRIM 51.43
  • Support Level
  • ANAB $19.86
  • NRIM $93.43
  • Resistance Level
  • ANAB $22.98
  • NRIM $95.61
  • Average True Range (ATR)
  • ANAB 1.00
  • NRIM 2.10
  • MACD
  • ANAB 0.35
  • NRIM 0.22
  • Stochastic Oscillator
  • ANAB 69.14
  • NRIM 50.53

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About NRIM Northrim BanCorp Inc

Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.

Share on Social Networks: